ArticleCancers2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Age-Specific Prognostic Models for Sepsis-Associated Acute Kidney Injury: A Multicenter Cohort Study.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Neutrophile-to-lymphocyte ratio predicts survival in patients aged 80 years and older undergoing radiotherapy: a single-center experience.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Association between leukocyte-derived inflammatory biomarkers and diabetic retinopathy progression in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Value of the systemic immune inflammation index in predicting the efficacy of neoadjuvant chemotherapy in patients with gastric cancer: a multicenter retrospective clinical study.Journal of gastrointestinal oncology · 2025Article
- SII as a predictor of mortality in patients with non-ST-segment elevation myocardial infarction and diabetes mellitus.Practical laboratory medicine · 2025Article
- Exploring the correlations between six serological inflammatory markers and different stages of type 2 diabetic retinopathy.Scientific reports · 2025Article
- Establishment of a nomogram based on Lasso Cox regression for albumin combined with systemic immune-inflammation index score to predict prognosis in advanced pancreatic carcinoma.Frontiers in oncology · 2025Article
- Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.BMJ oncology · 2025Article
- Survival prognosis evaluation in advanced breast cancer patients: a study on the application of the advanced lung cancer inflammation index.Frontiers in oncology · 2025Article
- High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 16 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGeriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection.
methodsWe built a multicenter, international retrospective study of 885 patients (<80 years: n = 417, 47.12%; ≥80 years: n = 468, 52.88%) with different tumor types treated with ICIs between 2011 and 2021 from 11 academic centers in the U.S. and Europe. The main outcome measures were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) stratified by age and circulating inflammatory levels (neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII)).
resultsPatients ≥80 years with low NLR (NLR-L) and SII (SII-L) had significantly higher ORR (vs. high NLR [NLR-H],
conclusionLower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.